Czechia· CZ-0271960
TYRUKO
A natalizumab product containing natalizumab, registered in Czechia by Sandoz GmbH, Kundl. The same ATC class is registered in 11 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Natalizumab is registered in 11 of 19 countries.
Countries holding a registration under ATC L04AG03 (natalizumab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 7 of them publish a price we can compare per daily dose
Natalizumab · ATC L04AG03
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- NATALIZUMAB
- Manufacturer
- Sandoz GmbH, Kundl
- Country
- Czechia (CZ)
- ATC code
- L04AG03
- ATC class
- Natalizumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02719601X15MLCZK 24600.71
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
323 interactions on record for natalizumab.
Graded by severity as the source publishes them — 301 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Natalizumab · interactions on record
323 records
- 301 severe
- 15 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Natalizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandTyrukoSandoz GmbH
- SwedenTyruko 300 mg Koncentrat till infusionsvätska, lösningSandoz GmbH
- PolandTyrukoSandoz GmbH
- BelgiumTyruko 300 mgSandoz
- IrelandTyruko 300 mg concentrate for solution for infusionPolpharma Biologics S.A.
- IcelandTyrukoSandoz GmbH*
- NorwayTyrukoSandoz GmbH
- SwitzerlandTyruko 300 mg / 15 ml, Konzentrat zur Herstellung einer InfusionslösungSandoz Pharmaceuticals AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tyruko, Tysabri
- Liechtenstein · Tyruko, Tysabri
- Norway · Tyruko, Tysabri
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4d05e7e0-6dc5-4b6d-9373-e9d2d19ee598 GET /v1/drugs/4d05e7e0-6dc5-4b6d-9373-e9d2d19ee598?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF CNC SOL",
"source": "sukl",
"strength": "300MG",
"pack_size": "1X15ML",
"substance": "NATALIZUMAB",
"cz_kod_sukl": "0271960",
"product_type": "BT",
"substance_codes": "14988",
"registration_state": "R",
"registration_number": "EU/1/23/1745/001"
}See everything about natalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.